These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 20940403

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
    Paul BT, Blanchard Z, Ridgway M, ElShamy WM.
    Oncogene; 2015 Jun 04; 34(23):3036-52. PubMed ID: 25132263
    [Abstract] [Full Text] [Related]

  • 3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z, Paul BT, Craft B, ElShamy WM.
    Breast Cancer Res; 2015 Jan 13; 17(1):5. PubMed ID: 25583261
    [Abstract] [Full Text] [Related]

  • 4. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
    Yan X, Fraser M, Qiu Q, Tsang BK.
    Gynecol Oncol; 2006 Aug 13; 102(2):348-55. PubMed ID: 16545436
    [Abstract] [Full Text] [Related]

  • 5. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
    Ding Q, Chen Y, Zhang Q, Guo Y, Huang Z, Dai L, Cao S.
    Mol Med Rep; 2015 Oct 13; 12(4):5100-8. PubMed ID: 26151347
    [Abstract] [Full Text] [Related]

  • 6. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
    Wu H, Cao Y, Weng D, Xing H, Song X, Zhou J, Xu G, Lu Y, Wang S, Ma D.
    Cancer Lett; 2008 Nov 28; 271(2):260-71. PubMed ID: 18657898
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
    Wu HJ, Wu HT, Weng DH, Xing H, Lu YP, Ma D.
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep 28; 42(9):612-6. PubMed ID: 17983517
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
    Zhao Z, Wang J, Tang J, Liu X, Zhong Q, Wang F, Hu W, Yuan Z, Nie C, Wei Y.
    Biochem J; 2012 Jun 01; 444(2):291-301. PubMed ID: 22394200
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y, Chen M.
    Cell Physiol Biochem; 2016 Jun 01; 39(1):242-52. PubMed ID: 27336949
    [Abstract] [Full Text] [Related]

  • 14. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
    Fraser M, Bai T, Tsang BK.
    Int J Cancer; 2008 Feb 01; 122(3):534-46. PubMed ID: 17918180
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin-induced caspase activation mediates PTEN cleavage in ovarian cancer cells: a potential mechanism of chemoresistance.
    Singh M, Chaudhry P, Fabi F, Asselin E.
    BMC Cancer; 2013 May 10; 13():233. PubMed ID: 23663432
    [Abstract] [Full Text] [Related]

  • 16. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
    Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, Krissansen GW, Qiao H, Sun X.
    FEBS J; 2014 Jan 10; 281(1):115-28. PubMed ID: 24165223
    [Abstract] [Full Text] [Related]

  • 17. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.
    Fetz V, Bier C, Habtemichael N, Schuon R, Schweitzer A, Kunkel M, Engels K, Kovács AF, Schneider S, Mann W, Stauber RH, Knauer SK.
    Int J Cancer; 2009 May 01; 124(9):2033-41. PubMed ID: 19130609
    [Abstract] [Full Text] [Related]

  • 18. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression.
    Wu H, Wang K, Liu W, Hao Q.
    Biochem Biophys Res Commun; 2014 Feb 07; 444(2):141-6. PubMed ID: 24434152
    [Abstract] [Full Text] [Related]

  • 19. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M, Qi Z, Liu B, Ren Y, Li H, Yang G, Zhang Q.
    Oncotarget; 2015 Sep 22; 6(28):25281-94. PubMed ID: 26325371
    [Abstract] [Full Text] [Related]

  • 20. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells.
    Tsubaki M, Takeda T, Ogawa N, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T, Nishida S.
    Leuk Res; 2015 Apr 22; 39(4):445-52. PubMed ID: 25726084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.